Correspondence 0001493152-24-042565 from Shuttle Pharmaceuticals Holdings, Inc. (SHPH)

Shuttle Pharmaceuticals Holdings, Inc.
Date: Oct. 25, 2024 · CIK: 0001757499 · Accession: 0001493152-24-042565

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-282231

Date

Oct. 25, 2024

Author

Chief

Form

CORRESP

Company

Shuttle Pharmaceuticals Holdings, Inc.

Letter

SHUTTLE PHARMACEUTICALS HOLDINGS, INC.

Professional Drive, Suite 260

Gaithersburg, MD 20879

(240) 430-4212

October 25, 2024

Via EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, D.C. 20549

Re: Shuttle Pharmaceuticals Holdings, Inc.

Registration Statement on Form S-1, as amended

File No. 333-282231

Acceleration Request

Requested Date: Tuesday, October 29, 2024

Requested Time: 5:00 PM Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Shuttle Pharmaceuticals Holdings, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its registration statement on Form S-1 (File No. 333-282231) so that it may become effective at 5:00 p.m. Eastern Time on Tuesday, October 29, 2024, or at such time as the Registrant may request by telephone to the staff (the “Staff”) of the Securities and Exchange Commission. In addition, the Registrant hereby authorizes Megan J. Penick, Esq. of Dorsey & Whitney LLP, counsel for the Registrant, to make such request on the Registrant’s behalf.

Very
truly yours,
Shuttle
Pharmaceuticals Holdings, Inc.

Show Raw Text

CORRESP
1
filename1.htm

SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.

401
Professional Drive, Suite 260

Gaithersburg,
MD 20879

(240)
430-4212

October
25, 2024

Via
EDGAR

U.S.
Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

    Re:
    Shuttle
    Pharmaceuticals Holdings, Inc.

    Registration
    Statement on Form S-1, as amended

    File
    No. 333-282231

Acceleration
Request

    Requested
    Date:
    Tuesday,
    October 29, 2024

    Requested
    Time:
    5:00
    PM Eastern Time

Ladies
and Gentlemen:

Pursuant
to Rule 461 promulgated under the Securities Act of 1933, as amended, Shuttle Pharmaceuticals Holdings, Inc. (the “Registrant”)
hereby requests acceleration of the effective date of its registration statement on Form S-1 (File No. 333-282231) so that it may become
effective at 5:00 p.m. Eastern Time on Tuesday, October 29, 2024, or at such time as the Registrant may request by telephone to the staff
(the “Staff”) of the Securities and Exchange Commission. In addition, the Registrant hereby authorizes Megan J. Penick, Esq.
of Dorsey & Whitney LLP, counsel for the Registrant, to make such request on the Registrant’s behalf.

    Very
    truly yours,

    Shuttle
    Pharmaceuticals Holdings, Inc.

    /s/
    Anatoly Dritschilo

    Name:

    Anatoly
    Dritschilo

    Title:
    Chief
    Executive Officer and

    Chairman
    of the Board of Directors

SecProbe.io